Actinic keratosis L57.0

Author: Prof. Dr. med. Peter Altmeyer

Co-Autors: Julian Baur, Dr. med. Nikolas Bounas-Pyrros

All authors of this article

Last updated on: 17.10.2026

Dieser Artikel auf Deutsch

Synonym(s)

Actinic keratoses; Actinic keratosis; AK; crasse de Vieillard; early in situ SCC type AKI; Early in situ SCC Type AKII; In situ SCC Type AKIII; Irritated actinic keratoses; keratoma senile; Keratosis actinic; keratosis senilis; keratosis solaris; KIN; SCC type actinic keratosis; solar keratosis

History
This section has been translated automatically.

Dubreuilh, 1896; Freudenthal, 1926

Definition
This section has been translated automatically.

In fair-skinned, photosensitive individuals, solar damage to the skin resulting from chronic, cumulative exposure to light (duration of exposure > 10 to 60 years), with formation of single or multiple, circumscribed or diffuse, reddish or red-brownish spots, papules, plaques, or nodules. Actinic keratoses (AK) are now defined as noninvasive, early (in situ) squamous cell carcinomas. This view is clarified by new naming conventions such as SCC (squamous cell carcinoma in situ) of the actinic keratosis type or KIN (keratinocytic intraepidermal neoplasia).

Classification
This section has been translated automatically.

A treatment-relevant clinical classification essentially refers to the extent and number of actinic keratoses (AK):

  • Patients with few (<5) single AK lesions
  • Patients with multiple (6 and >6) AK lesions
  • Patients with field carcinomatization
  • Patients with concomitant immunosuppression

m>w

The individual lesion can be classified from a clinical point of view as follows

This classification is a roughly indicative clinical classification. The variants shown can usually be clearly defined and assigned. However, it is not uncommon for mixed types to develop (e.g. development of an erythematous type with a circumscribed keratotic component).

Clinical and histological classification of actinic keratoses
Clinic Histology
Erythematous type Bowenoid type/atrophic type
Keratotic type/cornu-cutaneum type Hypertrophic type
Acantholytic type
Pigmented type Pigmented type
Lichenoid type (lichen planus type) Lichenoid type

Occurrence/Epidemiology
This section has been translated automatically.

Fair-skinned, red-haired or blonde individuals(skin type I/II according to Fitzpatrick) with high chronic sun exposure have a varying risk of developing actinic keratoses, depending on the intensity of the UV rays and their age.

The number of new cases is estimated at 240,000/year. It is assumed that around 1.7 million people in Germany are currently undergoing dermatological treatment for actinic keratosis (Schaefer 2014).

  • Prevalence (Central Europe; in patients > 40 years): 6-15%.
  • Prevalence (USA; in patients > 40 years): 11-26%.
  • Prevalence (Australia; in patients > 40 years): 45-60%.
  • Prevalence (Central Europe; in patients > 70 years): 52%.

Etiopathogenesis
This section has been translated automatically.

Multiplicative factors (e.g. hair color, positive family history, degree of tanning, sun exposure, especially UV rays) play a significant role in the development of the disease:

I. Radiation

a) UV rays: UVB rays induce so-called signature mutations (pyrimidine dimers) in the basal cell layer. In addition, long-wave UVA rays have an immunosuppressive effect. Carcinogenesis occurs long before visible lesions develop. In UV-exposed (non-lesional) skin, key mutations (so-called driver mutations) can be detected as the earliest molecular biological correlate of carcinogenesis in around 25% of all cases. UV rays lead to point mutations in one of the numerous kinetochore genes that code for a kinetochore protein. A kinetochore (Greek kínesis 'movement' and chōros 'place') is a special, plate- or hemispherical structure made of proteins and DNA segments that sits on the side of the centromere and serves as an attachment point for the fibers of the spindle apparatus during nuclear division processes. The upregulation of various kinetochore genes has been demonstrated. Kinetochore genes have been detected in various malignant tumors, including actinic keratoses and squamous cell carcinoma of the skin (KNSTRN gene).

UVA rays lead to reduced expression of the Notch signaling pathway in squamous cell carcinomas. The Notch 1 protein regulates (via p21) numerous cellular processes in keratinocytes such as cell differentiation, proliferation and apoptosis. A lack of Notch, as demonstrated in studies on squamous cell carcinomas, favors their occurrence.

UVB rays also lead to a transition from cytidine to thymidine in the tumor suppressor gene Tp53. This mutation can be detected in > 50% of all AK. When functioning normally, P53 plays an important role in the regulation of cell growth. A loss of function leads to uncontrolled growth of the keratinocytes. UVB rays also induce H-Ras mutations. These are detected in 21% of squamous cell carcinomas. The H-Ras gene product plays an important role in the Erk1/Erk2 signaling pathway. The mutation of H-Ras leads to an altered Ras protein and to increased cell production.

b) X-rays/ionizing radiation

c) Infrared radiation

II Chemical carcinogens

Chemical carcinogens such as aromatic hydrocarbons (see MOAH below) or arsenic are recognized as full-fledged carcinogens in the induction of cutaneous PEKs.

III Biological carcinogens

HPV: The proven high proportion (> 80%) of oncogenic HPV (human papillomaviruses) in actinic keratoses suggests that HPV could be etiologically relevant in combination with UV radiation. In actinic keratoses, a prevalence of HPV in organ transplants between 40 to 90% vs. 35 to 85% in immunocompetent patients was found. The HPV types are mostly epidermodysplasia verruciformis types.

IV. Predisposition factors

a) Immunosuppression: >30% of organ transplant patients have at least 5 actinic keratoses, with skin types I/II also being preferentially affected. Furthermore, immunosuppressed patients show a more aggressive growth behavior with a more rapid transition to squamous cell carcinoma. Organ transplant recipients have an approx. 250-fold higher risk of AKs and an approx. 100-fold higher risk of invasive cSCC.

b) Clinical syndromes that predispose to actinic keratoses:

  1. Albinism
  2. Rothmund-Thomson syndrome
  3. Cockayne syndrome
  4. Xeroderma pigmentosum
  5. Bloom syndrome

Elevated COX-2 (see cyclooxygenases below) and prostaglandin E2 levels have been found in actinic keratoses (see diclofenac below).

Manifestation
This section has been translated automatically.

Occurring mainly in fair-skinned, sunburn-prone and elderly people. Men are affected more frequently than women. Actinic keratoses are the first clinically manifest skin lesions in a UV-damaged skin area, where further lesions can potentially develop. This is referred to as"field carcinization".

Localization
This section has been translated automatically.

Chronically light-exposed skin areas of the scalp, especially forehead, bald head, nose, auricles, cheeks, back of the hands, red of the lips (cheilitis actinica). Less frequently: décolleté, extensor side of the forearms, back of the hands, lower legs.

Clinic
This section has been translated automatically.

Erythematous actinic keratosis: Initially, round, oval, or irregular papules or plaques measuring a few millimeters in size, always sharply demarcated, with inflammatory redness, and often interspersed with telangiectasias, featuring a rough, horny surface. Gradual increase in size (up to 1 cm or > 1 cm). Prone to bleeding following minor injuries.

Under reflected light microscopy, yellowish follicular hyperkeratosis, interfollicular erythema, scaling, and white circles around hair follicles are evident.

Actinic keratosis, keratotic type/cornu cutaneum type: Papules and plaques with the formation of whitish-gray, but also yellowish to brown, or gray-black, horny deposits of varying thickness that are often firmly adherent to the underlying skin. In the keratotic type, irregularly shaped, firmly adherent skin horns may develop (see also cornum cutaneum).

Pigmented type: Actinic keratoses with a brownish tinge due to increased pigmentation, tending to grow diffusely.

Lichenoid type (lichen planus type—related to the erythematous type):Clinically, deep red spots, papules, or plaques ranging from 0.2 to 2.0 cm in size—and sometimes larger—are observed, with a shiny, smooth, or rough surface. Histologically, features of lichen planus are present, including acanthosis, hypergranulosis, and orthohyperkeratosis, as well as a subepithelial, band-like, lichenoid, round-cell infiltrate.

Clinically, the severity is defined according to Olsen (Grades I–III) (see below:Clinical Classification of Actinic Keratosis). A well-evaluated “scoring” index for the quantitative and qualitative assessment of actinic keratoses on the head is the AKASI (acronym for “actinic keratosis area and severity index”) (Dirschka T et al. 2017). 

Irritated actinic keratoses: This phenomenon can be observed approximately 1 week after the start of cytostatic therapy, e.g., with 5-fluorouracil, and is accompanied by redness, swelling, and scaling—apparently as a sign of a cytotoxic effect (cytostatic drugs). 

Histology
This section has been translated automatically.

The histological picture is characterized by hyperkeratosis and parakeratosis on acanthotic, widened, or atrophic epithelium. Atypical pleomorphic keratinocytes are scattered throughout the epithelial band. Displaced nucleus-cytoplasm ratio; increased mitoses. Isolated dyskeratoses are always present, characterized by an amorphous, eosinophilic cytoplasm with a pyknotic or absent nucleus. Rare suprabasal acantholysis. Partial inflammatory infiltrate. Invasiveness (i.e., invasion into the papillary body) is not present in actinic keratosis (by definition). An important differential diagnostic criterion for actinic keratosis (distinguishing it fromBowen’s disease) is the preservation of the acral adnexal structures: infundibulum, acrosyringium. The excretory ducts wind through the altered surface epithelium in a street-like pattern.

Hypertrophic actinic keratosis: acanthosis, mild papillomatosis, strikingly pronounced hyperkeratosis and parakeratosis. Hyperkeratosis can lead to a grotesque disproportion between epithelial thickness and the stratum corneum. This histological finding corresponds to the clinical presentation ofcornu cutaneum.

Atrophic actinic keratosis: A flat, atrophic epithelial band with loss of the reticules; mild hyperkeratosis; cellular atypia mostly in the lower third of the epithelium. Here, focal protrusions extend toward the dermis. No invasiveness!

Bowenoid actinic keratosis: Hyperkeratosis and parakeratosis on acanthotic, widened epithelium. Atypical, pleomorphic keratinocytes are scattered in dense clusters across the epithelial band. In addition, giant epithelial cells as well as numerous bizarre mitoses and dyskeratoses are present. Differentiation from Bowen’s disease is achieved by demonstrating the presence of unaffected adnexal structures.

Acantholytic actinic keratosis: Suprabasal acantholysis is present in addition to the typical features of actinic keratosis.

Pigmented actinic keratosis: In addition to the epithelial changes characteristic of actinic keratosis, there is concurrent melanocyte proliferation and increased pigment deposition in the basal keratinocytes.

Lichenoid actinic keratosis: Usually presents as atrophic actinic keratosis with an accompanying, pronounced lichenoid (band-like) infiltrate in the upper dermis. Numerous dyskeratoses are common.

Regarding the histological classification based on the degree of dysplasia (KIN I–III), seeKIN below.

Differential diagnosis
This section has been translated automatically.

Clinical:

  • Seborrheic wart: relatively dull surface texture, usually uniform pigmentation, no rough keratosis on the surface; 
  • Arsenic keratoses: a rare variant of actinic keratosis (usually localized to the palms and soles) that is rarely encountered today;  
  • Chronic discoid lupus erythematosus: red, scaly plaques with well-defined borders; no history of chronic UV damage;   
  • Bowen’s disease: usually a solitary plaque, clinically difficult to distinguish; 
  • Basal cell carcinoma: a well-defined, grayish-shiny plaque that becomes more prominent when the skin is stretched;
  • Malignant solarlentigo: non-palpable, rounded spot with a smooth surface, dark brown to black-brown in color.  

Histologically:

  • Verruca seborrhoica: irritated forms of verruca seborrhoica; not always easily distinguishable due to the Borst-Jadassohn phenomenon; however, the broad-based cellular polymorphism characteristic of actinic keratosis is absent; 
  • Lentigo maligna: In lentigo maligna, the pronounced polymorphism of keratinocytes is absent; irregular proliferation of atypical melanocytes that penetrate the epithelial layer; this phenomenon is absent in actinic keratosis.
  • Superficial basal cell carcinoma: rather well-defined, basaloid epithelial proliferations separated from the normal epithelium; wide clefts extending into the surrounding connective tissue;
  • Actinic porokeratosis: Typical features include columnar parakeratosis cones; beneath the parakeratosis are dyskeratotic cells, which are otherwise generally absent.        

External therapy
This section has been translated automatically.

Selected lesion- and field-targeted treatment options for AK (as per the EDF guidelines)  
Curettage 1 time, repeat up to 2 times
Cryotherapy 1 time, multiple repetitions possible
CO₂ laser 1 time, multiple sessions possible
Er:YAG laser 1 session, multiple sessions possible
5-FU (0.5%) + SA (10%) Once daily for 6–12 weeks
5-ALA PDT Generally 1 hour penetration time
MAL-PDT i. General: 2.5-hour penetration time
 
Diclofenac (3%) in a 2.5% hyaluronic acid carrier gel   2 times daily for 60–90 days
5-FU (5%) 1 or 2 times daily for 2–4 weeks
Imiquimod (3.75%) Once a day for 2 weeks, followed by a 14-day break (1 or 2 cycles)

 

 

 

 

 

 

 

 

 

 

 

Alternatives: 

  • 5-Fluorouracil in combination with salicylic acid and DMSO (Actikerall®). 1 g of the solution contains 5 mg of fluorouracil, 100 mg of salicylic acid, and 80 mg of dimethyl sulfoxide. This combination preparation is used for flat or moderately thickened actinic keratoses. The colorless varnish is applied once daily strictly to the lesions until complete healing is achieved. Multiple actinic keratoses (up to 10 lesions) can be treated simultaneously (empirical data are available on this). The total area of skin to be treated with Actikerall should not exceed 25cm². (See also No. 757 GOÄ)
  • 5-Fluorouracil(as monotherapy): For multiple, extensive actinic keratoses, topical treatment with a 5% 5-fluorouracil ointment (e.g.,Efudix®) is possible. For monotherapy, apply the 5-fluorouracil ointment 1 to 2 times daily; duration of treatment is 3–6 weeks. The area to be treated must be < 500cm². When combined with curettage: Immediately after curettage, apply a thick layer of 5-fluorouracil ointment to the curetted lesion; reapply every other day. For lesions < 1 cm, use a 5-fluorouracil patch every 2–3 days. 
  • A slightly lower-concentration fluorouracil cream(Tolak®40 mg/g cream) may be used for non-hyperkeratotic, non-hypertrophic actinic keratoses (Grades I and II according to Olsen) on the face, ears, and/or scalp. Dosage: Once daily for 4 weeks.Caution!When using 5-fluorouracil, inform the patient about the method of application and side effects! Eye protection!
  • Alternative combination: 5-fluorouracil + retinoids: In cases of multiple, extensive lesions, good results have also been reported with the use of a 5%5-fluorouracil ointment in combination with isotretinoin (e.g., Isotretinoin ratiopharm; Isoderm). Apply 5% 5-fluorouracil (e.g., Efudix ointment) twice daily; take isotretinoin 10–20 mg/day orally; treatment duration: 3–5 weeks. Severe inflammatory reactions are to be expected; if necessary, temporarily use glucocorticoid-containing creams such as prednicarbate0.25% (e.g., DermatopCream®); systemic antibiotics should be administered in case of superinfection.
  • Imiquimod (Aldara® 5%, Zyclara® 3.5%): Topical immunomodulation with imiquimod 5% 1–3 times per week for a total of 8–16 weeks (U.S.: 2 times per week for 16 weeks). Local inflammation occurs at the site of the actinic keratosis, not on healthy skin. If irritation is too severe, reduce the application frequency to twice a week. The success of this therapy has been demonstrated by numerous studies; the cure rate is 40–50%. This therapy is approved in Germany. For Aldara, treatment is limited to a 25cm²treatment area. There is no such limitation for Zyclara. 
  • Photodynamic therapy: For single lesions, patch photodynamic therapy (patch-PDT; Alacare® for up to 6 single lesions) is a good alternative. 
  • Photodynamic Daylight Therapy: Photodynamic daylight therapy with methyl-ALA is also suitable for single lesions. Methyl-ALA (Luxerm®) accumulates in the tumor cells and is converted into the photosensitizer protoporphyrin IX, which is effective under daylight (a benefit for the patient!).       

Topical treatments for field cancerization:

  • Diclofenac: Very good results have been achieved with the local, well-tolerated application of a 3%diclofenac gel(Solaraze®,Solacutan®; twice daily). No limitation on the treatment area! This mechanism induces apoptosis and suppresses angiogenesis by inhibiting the arachidonic acid cycle. The literature reports remission rates of 40% for clinically visible lesions. 

Alternatives: 

  • Topicalretinoids such as 0.3%adapalene gel andtazarotene gel have also been shown to be effective in various clinical studies (off-label use). However, topical skin irritation, particularly with long-term therapy, must be taken into account.
  • Photodynamic therapy: For field cancerization, local photosensitization with 20% delta-aminolevulinic acid (ALA) followed by irradiation with infrared light is appropriate.
  • Photosensitization with methyl-ALA and irradiation with Aktilite®. 
  • Tirbanibulin (Klisyri® 10 mg/g, once daily for 5 days) as a selectively antiproliferative tubulin polymerization inhibitor. For mild actinic keratoses, apply once daily for a total of 5 days. As a rule, discrete to moderate local erythema develops. A reevaluation should be performed after 8 weeks.  

Operative therapie
This section has been translated automatically.

For the lesion-directed therapy procedures listed below, it is generally recommended to arrange for a meaningful histological examination of the scraped material.

  • Lesion-directed curettage: After prior local anesthesia for isolated actinic keratoses, curettage of the lesion with a flat sharp curette. Actinic keratoses usually detach easily in toto. Histological examination of the scraped material is useful.
  • Lesion-directed laser therapy with ablative laser (e.g., erbium YAG laser) have a very good response rate. Ablative laser treatment with an Er:YAG laser showed a nearly 90% healing rate. It is recommended to take curettage material immediately before laser treatment for histological confirmation of the findings.
  • Lesion-directed electrocautery with a ball: Pass the ball over the lesion with a weak current and delicately curette with a curette.
  • Lesion-directed cryosurgery with cotton swab: Especially in case of several smaller foci, this treatment is a good alternative to curettage. Immerse cotton swab in liquid nitrogen, press on the lesion continuously for 5-10 sec.
  • Lesion-directed cryosurgery in an open spray procedure: For large-area actinic keratoses with or without local anesthesia. Spray lesion briefly so that the area is covered with a white layer of ice. If necessary, repeat the procedure after thawing the lesion. Protect surrounding skin by moulage (e.g., perilesional application of a thick layer of Vaseline).

Progression/forecast
This section has been translated automatically.

The guidelines (Stockfleth 2016) assume a low (0-7.2%) probability of complete spontaneous regression.

The data on the development of squamous cell carcinomas on the basis of actinic keratoses (AK) vary considerably. They are indicated with 0.1%- 20%. A higher risk can be expected if > 5 AKs are present. In this clientele, the total risk of developing an invasive squamous cell carcinoma within 10 years is assumed to be 6.1-10% (Hommel 2016).

How does the progression of AK into squamous cell carcinoma proceed? It was assumed that an increasing intraepidermal stratification disorder of AK leads to squamous cell carcinoma. First, pleomorphic keratinocytes develop in the lower third of the epidermis (CHIN I) before they also penetrate higher epidermal layers (CHIN II/III). Only then would infiltrating growth occur. This formalistic progression model, however, does not adequately map the transformation of AK into an invasive squamous cell carcinoma, as invasiveness can develop from any KIN stage (Fernandez-Figueras 2015).

Prophylaxis
This section has been translated automatically.

Preventing excessive sun exposure through the use of clothing, chemical (e.g., Daylong Actinica), and other physical sun protection measures, as well as regular preventive checkups.

Recent studies (Chen et al., 2015) indicate that taking vitamin B3 (2 x 500 mg) has a UV-protective effect. The formation of new actinic keratoses is significantly reduced, by 13% after 12 months of therapy. 

There is positive individual experience and a moderately robust body of research regarding the topical use of photolysinsin combination with passive, chemical-physical broad-spectrum protection (e.g.,Eryfotona®with a cumulative total of a few hundred participants) for mild actinic keratoses. 

Avoid photosensitizing or phototoxic medications, such as hydrochlorothiazide.

Phytotherapy external
This section has been translated automatically.

Ingenolmebutate: An active ingredient isolated from common spurge—the drugPicato®was withdrawn from the market in 2020 due to concerns about the potential development of malignant tumors.

Studies indicate good efficacy of lipophilic Viscum album extract : Iscador Viscum A. 10% Extr. Res. 5 g ointment (PZN: 08038982). The response rate (complete and partial remission) was 71%, and the complete healing rate was 15% (Königsberger K et al. 2024).

A recent randomized, placebo-controlled, double-blind study is investigating the effect of a green tea extract (10% sinecatechin ointment) on actinic keratoses on the face and scalp. 

Practical tips
This section has been translated automatically.

GOÄ Tips:

Treatment includes no. 1 GOÄ (consultation), no. 7 GOÄ (examination of skin organ), 750 GOÄ (dermoscopy), if necessary video dermoscopy (no. 612 GOÄ analogue).

No. 612 GOÄ analogue and No. 750 GOÄ are to be applied next to each other if they refer to different skin changes. (750 for melanocytic nevus, 612 analogue for actinic keratosis).

No. 744 GOÄ (80 points) is used for a skin punch. The number is to be charged only once.

No. 303 GOÄ concerns a test biopsy with a needle, e.g. 2mm punch biopsy which is not sutured (80 points). It can be billed several times (e.g. for the evaluation of a marginal infiltration of a tumorous lesion - sclerodermiform basal cell carcinoma).

No. 2401 GOÄ (133 points) concerns a sample biopsy. The number defines an excision. If necessary, it can be billed several times.

No. 2403 GOÄ concerns the therapeutic excision of a small tumour (up to the size of a cherry stone). The number can be charged more than once

No. 2404 GOÄ concerns the therapeutic excision of a larger tumour (from the size of a cherry stone). Remark: On head and hands every finding is considered as large (Lit Haut 03/16). The figure can be applied more than once.

Further therapeutic services:

No. 745 GOÄ (wart removal with sharp spoon) can be applied analogously for a curettage.

No. 746 GOÄ (electrolysis) can be applied as electrodissection, also in addition to No. 745 GOÄ analogously.

No. 757 GOÄ chemosurgical treatment of a precancerous lesion, e.g. with fluorouracil, can be charged only once for one lesion, even in the case of several sessions. No. 757 can be charged several times for several lesions.

Laser treatments of an actinic keratosis: according to the recommendations of the German Medical Association (BÄK of 2002, supplement and specification for actinic keratoses in the DÄB of 27.12.2010) the following numbers are to be charged:

  • No. 2440 GOÄ analog (surgical removal of a nevus flammeus)
  • alternatively no. 2885 GOÄ analog (removal of a small blood vessel tumour)
  • alternatively no. 2886 GOÄ analog. (Removal of a large blood vessel tumour)
  • No. 444 GOÄ: (surcharge for outpatient performance of surgical services rated at 800-1199). The approach is justified (Lit Haut 03/16) is however often disputed.

The recommendations for laser ablation listed here correlate with the S1-guideline of the Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) for the treatment of actinic keratoses, which was lead-managed by the Deutsche Dermatologische Gesellschaft (German Dermatological Society). According to this guideline, ablative laser treatment of actinic keratoses is a highly effective therapy option, with described complete remissions of 90-91%. This high complete remission rate particularly justifies this therapeutic approach, which takes into account the clinically not always noticeable transition of actinic keratosis into an invasive growing squamous cell carcinoma.

Photodynamic therapy of actinic keratosis: to be applied according to the recommendations of the German Medical Association (DÄB of 18.1.2002) are the following numbers:

  • NR: 5442 GOÄ(static renal scintigraphy) analogous as photodynamic diagnostics
  • No. 566 GOÄ (phototherapy of a newborn) analogously as photodynamic light irradiation, up to 2 x in the treatment case.
  • No. 5800 GOÄ (preparation of a radiation plan) analogously as radiation plan for photodynamic therapy. The number is to be applied once per treatment case.
  • No. 5802 GOÄ (orthovoltage irradiation per fraction). This figure is used as a supplementary figure in addition to No. 566 GOÄ for 2 further irradiation fields.
  • No. 5803 GOÄ (supplement to No. 5802) analogous . This figure is applied as a supplementary figure in addition to no. 566 GOÄ for each additional irradiation field.
  • No. 209 GOÄ: Application of the photosensitizer
  • No. 200 GOÄ: Application of the occlusive tape
  • No. 530 GOÄ: Application of a cold pack.
  • No. 745 GOÄ. In case of pre-treatment of a lesion, the figure for curettage can be applied.

Literature
This section has been translated automatically.

  1. Ackerman AB et al. (2006) Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 155: 9-22
  2. Braakhuis BJ et al. (2003) A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 63: 1727–1730
  3. Chen AC et al. (2015) A Phase 3 Randomized Trial of Nicotinamide for Skin Cancer Chemoprevention. N Engl J Med 373:1618–1626.
  4. Dirschka T et al. (2017) A proposed scoring system for assessing the severity of actinic keratosis on the head: actinic keratosis area and severity index. J Eur Acad Dermatol Venereol 31:1295–1302
  5. Dubreuilh WA (1896) On circumscribed hyperkeratosis. Ann Dermatol Venereol 27: 1158-1164
  6. Fernández-Figueras MT et al. (2015) Actinic keratosis with atypical basal cells (AK I) is the most common lesion
  7. associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 29:991–997.
  8. Freudenthal W (1926) Verruca senilis and keratoma senile. Arch Dermatol Syphilol (Berlin) 158: 539–544
  9. Fritsch C, Ruzicka Th (2003) Fluorescence Diagnosis and Photodynamic Therapy of Skin Diseases. Atlas and Handbook. Springer, Heidelberg, Berlin
  10. Hengge UR, Stark R (2001) Topical imiquimod for the treatment of intraepidermal carcinoma. Arch Dermatol 137: 709–711
  11. Hommel T et al (2016) Actinic keratoses. Hautarzt 67: 867-875
  12. Kang S et al. (2003) Assessment of adapalene gel for the treatment of actinic keratosis and lentigines: A randomized trial. J Am Acad Dermatol 49: 83–90
  13. Nakaseko H et al. (2003) Histological changes and the role of apoptosis following photodynamic therapy for actinic keratoses. Br J Dermatol 148: 122-127
  14. Nicolas M et al. (2003) Notch1 functions as a tumor suppressor in mouse skin.Nat Genet 33:416–421.
  15. Röwert-Huber J et al. (2007) Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 156 (Suppl 3) 8–12
  16. Schaefer I et al. (2014) Prevalence and risk factors of actinic keratoses in Germany—analysis of multisource data. J Eur Acad Dermatol Venereol 28:309–313.
  17. Stege H et al. (2017) New Approaches to the Prevention of Actinic Keratoses. Hautarzt 68: 354–358
  18. Stockfleth E et al. (2004) Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 140: 1542
  19. Werner RN et al. (2015) Evidence- and consensus-based (S3) Guidelines for the Treatment of Actinic
  20. Keratosis—International League of Dermatological Societies in cooperation with the European Dermatology Forum—Short version. J Eur Acad Dermatol Venereol 29: 2069–2079.
  21. Wolf JE et al. (2001) Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses. Int J Dermatol 40: 709–713
  22. Zeicher J et al. (2009) Placebo-controlled, double-blind, randomized pilot study of imiquimod 5% cream applied once per week for 6 months for the treatment of actinic keratoses. JAAD 60: 59–62
  23. Königsberger K et al. (2024) Viscum album lipophilic extract in actinic keratosis, cutaneous squamous cell carcinoma, and basal cell carcinoma: A retrospective case series. Complement Med Res 31 (3): 241–252. https://doi.org/10.1159/000537979

Disclaimer

Please ask your physician for a reliable diagnosis. This website is only meant as a reference.

Authors

Last updated on: 17.10.2026